OSE Immunotherapeutics – Key opinion leader webinar

Watch recent OSE Immunotherapeutics lung cancer-focused key opinion leader investor webinar.

The event features Dr Stephen Liu, medical oncologist, Georgetown University (Washington DC, United States), who discusses the unmet medical need and therapeutic landscape in lung cancer.

Professor Benjamin Besse, medical oncologist, director of clinical research at the Gustave Roussy Institute (Villejuif, France), presents the Artemia study, the registration Phase III clinical trial of Tedopi® in non-small cell lung cancer.

Soo Romanoff, managing director of healthcare at Edison Group, chairs the panel and Q&A.

About OSE Immunotherapeutics

OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immuno-oncology and immuno-inflammation. At the forefront of its portfolio is Tedopi®, a revolutionary cancer vaccine that has recently demonstrated promising outcomes in a Phase III study involving non-small cell lung cancer patients facing secondary resistance following checkpoint inhibitor treatment. The company’s R&D pipeline is robust and diverse, ensuring that its progress remains resilient and independent of any singular subsector.

For more information on OSE Immunotherapeutics, please read the latest updates on Edison’s website and visit the company’s website.